申请人:EURO-CELTIQUE S.A.
公开号:EP2067776A1
公开(公告)日:2009-06-10
Piperidine Compounds; compositions comprising a Piperidine Compound; and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression in an animal comprising administering to an animal in need thereof an effective amount of a Piperidine Compound are disclosed. In embodiment, the Piperidine Compound has the formula:
and pharmaceutically acceptable salts thereof, wherein Ar1, Ar2, X, R3, R4, and m are as disclosed herein.
哌啶化合物;包含哌啶化合物的组合物;以及治疗或预防疼痛、UI、溃疡、IBD、IBS、成瘾性疾病、帕金森病、帕金森综合症、焦虑症、癫痫、中风、癫痫发作、瘙痒症、精神病、认知障碍、记忆缺陷、脑功能受限的方法、本发明公开了一种哌啶化合物,可用于治疗动物的亨廷顿舞蹈症、肌萎缩性脊髓侧索硬化症、痴呆症、视网膜病变、肌肉痉挛、偏头痛、呕吐、运动障碍或抑郁症,包括向有需要的动物施用有效量的哌啶化合物。在实施方案中,哌啶化合物具有以下式子:
及其药学上可接受的盐,其中 Ar1、Ar2、X、R3、R4 和 m 如本文所公开。